CT-868
- Generic Name
- CT-868
A Study of CT-868 in Type 1 Diabetes Mellitus
Phase 2
Active, not recruiting
- Conditions
- ObeseType 1 Diabetes MellitusOverweight
- Interventions
- Device: CT-868 Pen Injector
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Carmot Therapeutics, Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT06062069
- Locations
- 🇺🇸
Carmot Therapeutics Investigational Site 121, Concord, California, United States
🇺🇸Carmot Therapeutics Investigational Site 125, Escondido, California, United States
🇺🇸Carmot Therapeutics Investigational Site 118, Aurora, Colorado, United States
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Carmot Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05794581
- Locations
- 🇺🇸
Carmot Clinical Research Unit 101, Chula Vista, California, United States
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Carmot Therapeutics, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT05110846
- Locations
- 🇲🇽
Carmot Clinical Center MX05, Mérida, Yucatan, Mexico
🇲🇽Carmot Clinical Center MX03, Mexico City, Mexico
🇲🇽Carmot Clinical Center MX04, Guadalajara, Jalisco, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath